2. Search Result
Search Result
Results for "

urinary bladder cancer

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W755252
    N-Butyl-N-(4-hydroxybutyl)nitrosamine

    BBN

    		 DNA Alkylator/Crosslinker Cancer
    N-Butyl-N-(4-hydroxybutyl)nitrosamine is a potent mutagen that can cause high-level of mutagenesis specifically in the epithelial cells (urothelial) of the urinary bladder. N-Butyl-N-(4-hydroxybutyl)nitrosamine is used to induce bladder cancer in rodents .
    N-Butyl-N-(4-hydroxybutyl)nitrosamine
  • HY-Y1117
    Melamine
    1 Publications Verification

    		 Apoptosis TGF-β Receptor NF-κB COX NADPH Oxidase ROS Kinase Neurological Disease Inflammation/Immunology
    Melamine is an orally active inducer of Apoptosis. Melamine induces animal disease models. Melamine affects the activity of Sertoli cell and can be used for research on male reproductive function. Melamine also has neurotoxicity and nephrotoxicity. Melamine induces cognitive impairment and acute kidney injury models. Melamine can also be used to induce bladder cancer and urinary stone models .
    Melamine
  • HY-A0033
    Darifenacin
    Maximum Cited Publications
    6 Publications Verification

    UK-88525

    		 mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin
  • HY-A0012
    Darifenacin hydrobromide
    Maximum Cited Publications
    6 Publications Verification

    UK-88525 hydrobromide

    		 mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin hydrobromide
  • HY-146358
    Anticancer agent 49

    		Microtubule/Tubulin Cancer
    Anticancer agent 49 (compound 69) is a broad spectrum anticancer agent. Anticancer agent 49 inhibits tubulin polymerization. Anticancer agent 49 shows antiproliferative activity. Anticancer agent 49 has the potential for the research of solid and hematological tumors .
    Anticancer agent 49
  • HY-A0012R
    Darifenacin hydrobromide (Standard)

    UK-88525 hydrobromide (Standard)

    		 Reference Standards mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin hydrobromide (Standard)
  • HY-146357
    Anticancer agent 48

    		Microtubule/Tubulin Cancer
    Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors .
    Anticancer agent 48

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: